Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal
NEW YORK, April 21 —
Eli Lilly committed roughly $7 billion to Legend Biotech's CARVYKTI franchise, sending LEGN up as much as 18% — its best day in three years.
- LEGN gained 9-18% on the session after multiple outlets confirmed the deal; shares traded near $24.93
- HC Wainwright reiterated Buy with a $50 price target, implying roughly 100% upside from recent levels
- Next catalyst: definitive deal terms plus CARVYKTI sales data in Legend's upcoming quarterly earnings report
What Actually Happened
Lilly is buying its way into CAR-T therapy — the class of cancer treatments that reprogram a patient's own immune cells to attack tumors. CARVYKTI, Legend's lead asset, already generates $1.0bn in trailing twelve-month revenue. That is real commercial traction, not a Phase 2 dream.
The deal puts Lilly in direct competition with the two CAR-T incumbents: Johnson & Johnson, Legend's existing partner on CARVYKTI, and Gilead, which sells rival therapy Yescarta.
Raymond James reiterated its positive stance, citing strong clinical trial data. HC Wainwright's $50 target says the Street thinks the current price badly undervalues the asset. At 21.7x forward earnings, LEGN is priced like a speculative biotech — not a company with $1 billion in revenue and a pharma giant writing checks.
The Catch
The deal terms are still approximate. "Roughly $7 billion" and "related strategic transaction" are doing heavy lifting. Until definitive terms land, the actual per-share value to LEGN holders is unknown.
CAR-T therapies also face a manufacturing bottleneck: each dose must be individually produced from a single patient's cells. Legend has been expanding US manufacturing capacity, but scaling a personalized therapy is not the same as scaling a pill. Gilead learned this with Yescarta, where production constraints slowed the commercial ramp.
Then there is the J&J question. Johnson & Johnson has an existing partnership with Legend on CARVYKTI. Whether J&J holds rights that complicate Lilly's transaction — or force a renegotiation — matters enormously for the final number shareholders receive.
Bottom Line
This deal settles one debate. When Eli Lilly, one of the world's largest pharma companies, pays $7bn to enter your market through your product, no one asks "is this real?" anymore.
The open question is whether $7bn is enough. HC Wainwright's $50 target is double the current price. Competing bids are plausible in a hot oncology M&A market. The numbers to watch: definitive deal terms and any signal from J&J about its own stake in the CARVYKTI relationship.
Legend Biotech does not yet have a Basis Report. Generate a full LEGN equity report here to dig into the financials behind this deal.
Basis Report does not hold positions in securities discussed. This is not investment advice.